Comparison of COVID-19 antibody levels in school - aged children and healthy adults: evidence from a tertiary care hospital of Bangladesh
DOI:
https://doi.org/10.18203/2349-3291.ijcp20252208Keywords:
Age-dependent variation, Adult, Covid antibody, School aged childrenAbstract
Background: The immune response to COVID-19 varies among individuals based on multiple factors, including age, comorbidities and prior exposure to the virus. Understanding these variations is crucial for optimizing vaccination strategies and public health policies. This study was conducted in a tertiary-level hospital in Bangladesh to assess whether age influences COVID-19 antibody levels among school-aged children and healthy adults.
Methods: This cross-sectional observational study was conducted at Central Police Hospital, Dhaka, Bangladesh, between September 2022 and August 2024. Data were collected from two groups: children aged 3-15 years attending the Paediatric Outpatient Department and adults aged 25-76 years attending the Medicine Outpatient Department for routine medical visits. A total of 94 children and 112 adults were included in the study. All statistical analyses were conducted using statistical software SPSS version 26.0.
Results: The mean total antibody levels ranged from 94±14.6 in children aged 3-5 years to 98±15.1 in adults aged 41-60 years, with no significant difference across age groups (p=0.827). Regression analysis showed that age was not a significant predictor of antibody levels (β₁=0.015, p=0.252). Comorbidities in adults, including diabetes (96±15.1, p=0.612), hypertension (95±13.8, p=0.529) and heart disease (93±16.5, p=0.451), did not significantly affect antibody responses.
Conclusions: This study found that school-aged children exhibited significant COVID-19 antibody levels despite neither being vaccinated nor having a documented history of infection. In contrast, healthy adults achieved comparable antibody levels primarily through vaccination. Regression analysis confirmed that age was not a significant predictor of antibody levels and comorbidities did not have a notable impact on antibody responses in adults. These findings suggest that children may acquire antibodies through alternative mechanisms, such as asymptomatic exposure or passive immunity, while adults rely on vaccination for immune protection.
Metrics
References
Mondiale SO. Organization WH. Weekly Epidemiological Record. Weekly Epidemiological Record. Relevé épidémiologique hebdomadaire. 2022;97(08):49–60.
Hossain AT, Akter E, Manna RM, Ara T, Hossain MA, Tanvir KM, et al. Impact of COVID-19 on the utilization of maternal health services in Bangladesh: A division-level analysis. J Glob Health. 2024;14:05040. DOI: https://doi.org/10.7189/jogh.14.05040
Al Saba A, Sayem M, Al Rimon R, Sanyal M, Chakraborty S, Rahman MA, et al. Evaluating the seroprevalence of SARS-CoV-2 IgG in five different districts of Bangladesh. A seroepidemiological study. J Inf Publ Health. 2023;16(6):964–73. DOI: https://doi.org/10.1016/j.jiph.2023.04.013
Bhuiyan TR, Akhtar M, Akter A, Khaton F, Rahman SIA, Ferdous J, et al. Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection. IJID regions. 2022;2:198–203. DOI: https://doi.org/10.1016/j.ijregi.2022.01.013
Wong LSY, Loo EXL, Kang AYH, Lau HX, Tambyah PA, Tham EH. Age-related differences in immunological responses to SARS-CoV-2. The J Aller Clin Immunol Pract. 2020;8(10):3251–8. DOI: https://doi.org/10.1016/j.jaip.2020.08.026
Ahmed ZB, Razu MH, Akter F, Rabby MdRI, Karmaker P, Khan M. Seropositivity of SARS‐CoV‐2 IgG Antibody among People in Dhaka City during the Prevaccination Period. Angelillo IF, editor. BioMed Res Int. 2022;20(1):4451144. DOI: https://doi.org/10.1155/2022/4451144
Haq MA, Roy AK, Ahmed R, Kuddusi RU, Sinha M, Hossain MS, et al. Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh. Scientific Reports. 2024;14(1):11467. DOI: https://doi.org/10.1038/s41598-024-61922-6
Raqib R, Sarker P, Akhtar E, Nurul Huda TM, Haq MA, Roy AK, et al. Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021. PLoS One. 2022;17(5):268093. DOI: https://doi.org/10.1371/journal.pone.0268093
Collier DA, Ferreira IA, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417–22. DOI: https://doi.org/10.1101/2021.02.03.21251054
Das D, Raha FK, Adnan KM, Siraj MR, Shapla MJ, Shumy F, et al. Dynamic antibody response in SARS-CoV-2 infected patients and COVID-19 vaccine recipients alongside vaccine effectiveness in comorbid and multimorbid groups. Heliyon. 2023;9(5):679. DOI: https://doi.org/10.1016/j.heliyon.2023.e16349
Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. Lancet Global Health. 2021;9(3):257–66. DOI: https://doi.org/10.1016/S2214-109X(20)30544-1
Ali A, Waqar M, Akram A, Rafique S, Rehman G, Idrees M, et al. Seroprevalence of SARS-CoV-2: Insights into the epidemiology of the pandemic. Journal of Infection and Public Health. 2023;16(8):1256–61. DOI: https://doi.org/10.1016/j.jiph.2023.05.036
Kirwan PD, Foulkes S, Munro K, Sparkes D, Singh J, Henry A, et al. Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024. J Infect. 2024;89(5):106293. DOI: https://doi.org/10.1016/j.jinf.2024.106293
Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Mulligan MJ, et al. Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants. BioRxiv. 2021;2:97. DOI: https://doi.org/10.1101/2021.07.19.452771
Massarvva T. Clinical outcomes of COVID-19 amongst HIV patients: a systematic literature review. Epidemiol Heal. 2021;43:2867. DOI: https://doi.org/10.4178/epih.e2021036
Liang X, Shi L, Wang Y, Xiao W, Duan G, Yang H, et al. The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates. J Infect. 2020;81(3):44–7. DOI: https://doi.org/10.1016/j.jinf.2020.06.060
Hossain MB, Alam MZ, Islam MS, Sultan S, Faysal MM, Rima S, et al. COVID-19 vaccine hesitancy among the adult population in Bangladesh: A nationwide cross-sectional survey. PloS one. 2021;16(12):260821. DOI: https://doi.org/10.1371/journal.pone.0260821
Shrotri M, Fragaszy E, Nguyen V, Navaratnam AM, Geismar C, Beale S, et al. Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. Nature Communications. 2022;13(1):5780. DOI: https://doi.org/10.1038/s41467-022-33550-z
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022;6;386(1):35–46. DOI: https://doi.org/10.1056/NEJMoa2116298
Sorensen RJD, Barber RM, Pigott DM, Carter A, Spencer CN, Ostroff SM, et al. Variation in the COVID-19 infection-fatality ratio by age, time and geography during the pre-vaccine era: A systematic analysis. Lancet. 2022;399(10334):1469–88. DOI: https://doi.org/10.1016/S0140-6736(21)02867-1
Ryan FJ, Norton TS, McCafferty C, Blake SJ, Stevens NE, James J, et al. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. Cell Rep Med. 2023;4(3):3958. DOI: https://doi.org/10.1016/j.xcrm.2023.100971
Montgomery CL, Davenport A, Milovanovic L, Bagshaw SM, Rolfson DB, Rewa OG. COVID-19–associated outcomes of critical illness in patients with frailty: a cohort Study. Canadian Geriat J. 2024;27(3):307. DOI: https://doi.org/10.5770/cgj.27.731
Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;3:76. DOI: https://doi.org/10.1136/bmj-2021-068632
Cremer K, Frère J, Chatzis O, De Mendonca R, Minner F, Kabamba B, et al. SARS-CoV-2 antibody seroprevalence in children and workers from Belgian French-speaking primary schools. 2022 Available at: https://www.researchsquare. Accessed on 21 December 2024. DOI: https://doi.org/10.21203/rs.3.rs-1781857/v1
Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nature Immunol. 2021;22(1):25–31. DOI: https://doi.org/10.1038/s41590-020-00826-9
Downloads
Published
How to Cite
Issue
Section
